Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, published by Lippincott Williams & Wilkins, is a premier academic journal dedicated to the intricate field of gynecological pathology, serving a critical role in advancing the understanding of diseases related to women's reproductive health. Since its inception in 1982, this journal has established itself as a key resource for researchers, clinicians, and students, with a current impact factor that reflects its esteemed reputation; it is ranked in the Q2 category for both Obstetrics and Gynecology, as well as Pathology and Forensic Medicine, signifying its prominence in academic circles. The journal's scope encompasses a wide array of topics, including histopathological findings, diagnostic methodologies, and evolving therapeutic strategies, all pivotal to enhancing patient care. With a steadfast commitment to disseminating high-quality research until the projected year of 2024, the INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY is an essential read for those looking to stay abreast of the latest developments in this vital area of medical science.

GYNECOLOGIC AND OBSTETRIC INVESTIGATION, published by KARGER, is an influential journal dedicated to advancing the fields of obstetrics and gynecology. With an ISSN of 0378-7346 and E-ISSN 1423-002X, this esteemed publication has been disseminating pivotal research since 1895 and continues to serve as an authoritative source through its convergence until 2024. Renowned for its rigorous adherence to academic standards, it stands in the Q2 category for both Obstetrics and Gynecology and Reproductive Medicine as of 2023, reflecting its quality and impact within the scientific community. With Scopus rankings highlighting its commendable positions—Rank #66 in Obstetrics and Gynecology and Rank #31 in Reproductive Medicine—it is an essential resource for researchers, professionals, and students alike, fostering a deeper understanding of women’s health issues and innovative care practices. Despite not being an open-access journal, its contributions significantly influence current and future directions in clinical and translational research.

Gynecologic Oncology Reports is a pivotal interdisciplinary journal published by Elsevier Science Inc. that has been dedicated to advancing the understanding of women's health since its inception in 2014. This Open Access journal, available to a global audience, facilitates the dissemination of high-quality research in the fields of gynecology and oncology, allowing for the free exchange of knowledge and fostering collaboration among researchers, clinicians, and students. With an impact factor reflective of its commitment to clinical relevance, Gynecologic Oncology Reports holds a Q3 ranking in both obstetrics and gynecology as well as oncology categories, contributing to its visibility and the prestige of published work. Situated in the Netherlands and operating within an open-access framework, it ensures that critical findings and advancements reach a broad readership. The journal serves as a vital resource for those aiming to stay at the forefront of gynecologic oncology, promoting improved patient outcomes through cutting-edge research. As it converges towards its 10th anniversary in 2024, Gynecologic Oncology Reports continues to be an essential platform for scholarly communication in this important field.

INTERNATIONAL JOURNAL OF HYPERTHERMIA, published by Taylor & Francis Ltd, is a leading peer-reviewed journal dedicated to advancing the field of hyperthermia and its applications in medical science, particularly within cancer research and related disciplines. With an ISSN of 0265-6736 and an E-ISSN of 1464-5157, this journal has been a vital resource since its establishment in 1985, offering a platform for innovative research and clinical applications aimed at improving treatment outcomes. The journal is recognized with a Q2 category ranking in several fields, including Cancer Research and Physiological Medicine, reflecting its significant contribution to scientific knowledge and clinical practices. Furthermore, it has been Open Access since 2019, ensuring that cutting-edge research is accessible to a global audience. By facilitating the exchange of ideas and fostering collaborations among researchers, professionals, and students, the INTERNATIONAL JOURNAL OF HYPERTHERMIA serves as an essential resource in the quest to exploit hyperthermia’s full potential in therapeutic settings.

The Journal of Gynecologic Oncology, published by the Korean Society of Gynecology Oncology & Colposcopy, stands as a premier open access platform since 2011, dedicated to advancing the field of gynecologic oncology. With an ISSN of 2005-0380 and an E-ISSN of 2005-0399, this esteemed journal showcases high-quality research that drives innovation in treatment and care for women affected by gynecologic cancers. Based in South Korea, the journal spans an impressive timeline from 2009 to 2024 and holds a distinguished Q1 ranking in both Medicine (Miscellaneous) and Obstetrics and Gynecology, emphasizing its vital contributions to these fields. The journal is recognized for its rigorous peer-review process and is indexed in Scopus, with notable rankings of #35/209 and #128/404 in Obstetrics and Gynecology and Oncology respectively. As a vital resource for researchers, clinicians, and students alike, it aims to disseminate impactful findings that enhance patient care and foster collaboration across international boundaries.

Gynecologic Oncology, an esteemed journal published by Academic Press Inc Elsevier Science, stands at the forefront of research in the domains of Obstetrics and Gynecology and Oncology. With an exceptional track record dating from 1972 to 2024, this journal has established itself as a vital resource for scholars and practitioners alike, boasting a remarkable Q1 ranking in both fields as of 2023. Gynecologic Oncology not only ranks #13 out of 209 in Obstetrics and Gynecology and #72 out of 404 in Oncology but also operates within the top percentiles of academic influence, with a 94th percentile in Obstetrics and Gynecology and an 82nd percentile in Oncology on Scopus. Although the journal does not currently offer open access, it remains crucial for disseminating original research, reviews, and advances in the management and treatment of gynecological cancers. Researchers and health professionals will find this journal indispensable for staying informed on the latest advancements and breakthroughs in this vital area of medicine, fostering a deeper understanding and potentially transforming patient care practices.

Reports of Practical Oncology and Radiotherapy is a distinguished open-access journal dedicated to advancing the fields of oncology, radiotherapy, and cancer research. Published by VIA MEDICA since 2001, this journal serves as a critical platform for disseminating innovative research and practical findings that impact clinical practices and patient outcomes. With an emphasis on fostering collaboration and knowledge exchange among researchers, clinicians, and students, the journal has positioned itself within the Q3 and Q4 categories of renowned directories in oncology, radiology, and nuclear medicine as of 2023. Based in Gdansk, Poland, it provides unrestricted access to its articles, ensuring that crucial research reaches a wide audience. This dedication to open access reflects the journal's commitment to transparency and innovation in the fight against cancer, making it an invaluable resource in this vital field of study.

The Journal of Gynecologic Surgery is a pivotal publication dedicated to the field of gynecologic surgery, contributing to the advancement of knowledge and practices since its inception in 1989. Published by Mary Ann Liebert, Inc., this journal serves as an essential resource for researchers, clinicians, and students involved in obstetrics and gynecology. With an ISSN of 1042-4067 and an E-ISSN of 1557-7724, it provides critical insights into surgical techniques, innovations, and outcomes relevant to women's health. Although it currently does not offer open access, the content is valuable for professionals seeking to enhance their clinical skills and academic understanding. In the 2023 Scopus rankings, it is placed in the Q4 quartile for both Obstetrics and Gynecology and Surgery, reflecting its niche yet impactful role in these fields. The journal's ongoing repository of knowledge ensures that it remains a significant platform for the dissemination of scholarly research and practical applications in gynecologic surgery.

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.